Literature DB >> 24985374

[Analysis of survival rate of breast, cervical, and ovarian cancer patients during 2005-2010 in Zhejiang province, China].

Weiwei Gong1, Shenglan Luo, Ruying Hu, Hao Wang, Jin Pan, Fangrong Fei, Qingfang He, Min Yu2.   

Abstract

OBJECTIVE: To provide reference information for prognosis and control of female cancers by analyzing survival rates of breast, cervical and ovarian cancer patients during 2005-2010 in Zhejiang province.
METHODS: The morbidity and mortality data of 18 133 breast, cervical and ovarian cancer patients whose information were registered in health surveillance zone during 2005-2010 in Zhejiang were analyzed. The December 31(st), 2012 was set as the deadline of survival time. Observed survival rate (OS) and relative survival rate (RS) were calculated using SURV3.01 software and comparison between survival rates was conducted through Hakulinen's likely hood ratio test.
RESULTS: The 5-year OS of breast cancer, cervical cancer, and ovarian cancer were 76.89%, 70.79%, 2.59%, respectively during 2005-2010 in Zhejiang province. The 5-year RS of the three cancers were 80.26%, 73.89%, 55.17%, respectively. The 5-year RS of breast cancer, cervical cancer, and ovarian cancer in urban area were 83.11%, 77.87%, and 57.22% and 78.00%, 72.21%, and 53.83% in rural areas, respectively. The overall RS of urban patients was higher than the rural's (χ(2) = 24.98, 11.55 and 6.62, respectively, all P values < 0.05). The 5-year RS of breast cancer, which was grouped by age, showed that the 15-44 years group was the highest (83.40%), while 65-77 years group was the lowest (74.67%). The 5-year RS of cervical cancer decreased with age, with a 41.73% decrease from 83.83% (15-44 years group) to 42.10% ( ≥ 75 years group). The 15-44 years group showed the highest 5-year RS of ovarian cancer (74.30%), while ≥ 75 years group was the lowest (41.80%).
CONCLUSION: The prognosis of breast cancer and cervical cancer were relatively optimistic, while the ovarian cancer was not. The prognosis of female cancer patients in urban areas were better than in rural areas.

Entities:  

Mesh:

Year:  2014        PMID: 24985374

Source DB:  PubMed          Journal:  Zhonghua Yu Fang Yi Xue Za Zhi        ISSN: 0253-9624


  5 in total

1.  Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.

Authors:  Zhongyuan Tang; Weiwei Feng; Yiqing Yang; Qun Wang
Journal:  Drug Des Devel Ther       Date:  2019-09-17       Impact factor: 4.162

2.  Effect of time interval from diagnosis to treatment for cervical cancer on survival: A nationwide cohort study.

Authors:  Chao-Ping Chen; Pei-Tseng Kung; Yueh-Hsin Wang; Wen-Chen Tsai
Journal:  PLoS One       Date:  2019-09-04       Impact factor: 3.240

3.  Cost-effectiveness of 2-dose human papillomavirus vaccination for 12-year-old girls in Zhejiang Province: implications for China's expanded program on immunization.

Authors:  Yan Luo; Hanqing He; Xuewen Tang; Shenyu Wang; Jun Zhang; Ting Wu; Zhiping Chen
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

4.  Survival of gynecological cancers in Turkey: where are we at?

Authors:  Murat Gultekin; Selin Dundar; Irem Kucukyildiz; Mujdegul Zayifoglu Karaca; Guledal Boztas; Semra Hatice Turan; Ezgi Hacikamiloglu; Bekir Keskinkilic
Journal:  J Gynecol Oncol       Date:  2017-11       Impact factor: 4.401

5.  Cervical cancer diagnosis and treatment delays in the developing world: Evidence from a hospital-based study in Zambia.

Authors:  Jane Mwamba Mumba; Lackson Kasonka; Okola Basil Owiti; John Andrew; Mwansa Ketty Lubeya; Lufunda Lukama; Charlotte Kasempa; Susan C Msadabwe; Chester Kalinda
Journal:  Gynecol Oncol Rep       Date:  2021-05-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.